Serum Concentrations of TIM-3, LAG-3, and PD-1 in Patients with Hemorrhagic Fever with Renal Syndrome

被引:0
|
作者
Safranko, Zeljka Macak [1 ]
Jakopec, Lana [1 ]
Svagusa, Karla [1 ]
Krajinovic, Lidija Cvetko [1 ]
Tomasovic, Domagoj [1 ]
Lukic, Ljiljana [1 ]
Markotic, Alemka [1 ,2 ,3 ]
机构
[1] Univ Hosp Infect Dis Dr Fran Mihaljev, Res Unit, Zagreb 10000, Croatia
[2] Univ Rijeka, Fac Med, Rijeka 51000, Croatia
[3] Catholic Univ Croatia, Fac Med, Zagreb 10000, Croatia
来源
LIFE-BASEL | 2024年 / 14卷 / 05期
关键词
orthohantavirus; HFRS; PUUV; inhibitory receptors; immune regulations; TIM-3; LAG-3; PD-1; T-CELL EXHAUSTION; INHIBITORY RECEPTORS; EXPRESSION; VIRUS; PROTEIN; HANTAVIRUSES; ACTIVATION; MACROPHAGE; AUTOIMMUNE; RESPONSES;
D O I
10.3390/life14050551
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hemorrhagic fever with renal syndrome (HFRS) is a rodent-borne disease widespread in Europe and Asia. HFRS is caused by negative-sensed single-stranded RNA orthohantaviruses transmitted to humans through inhaling aerosolized excreta of infected rodents. Symptoms of HFRS include acute kidney injury, thrombocytopenia, hemorrhages, and hypotension. The immune response raised against viral antigens plays an important role in the pathogenesis of HFRS. Inhibitory co-receptors are essential in regulating immune responses, mitigating immunopathogenesis, and reducing tissue damage. Our research showed an increased soluble form of inhibitory co-receptors TIM-3, LAG-3, and PD-1 in HFRS patients associated with disease severity. Our study aimed to investigate the impact of HFRS on the concentrations of soluble forms of inhibitory receptors TIM-3, LAG-3, and PD-1 in the patient's serum and the potential correlation with key clinical parameters. Our study aimed to investigate the impact of HFRS on the concentrations of soluble forms of inhibitory receptors TIM-3, LAG-3, and PD-1 in the patient's serum and their possible association with relevant clinical parameters. Using multiplex immunoassay, we found elevated levels of TIM-3, LAG-3, and PD-1 proteins in the serum of HFRS patients. Furthermore, increased levels were associated with creatinine, urea, lactate dehydrogenase concentrations, and platelet count. These findings suggest that these proteins play a role in regulating the immune response and disease progression.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models
    Mimura, Kosaku
    Kua, Ley-Fang
    Xiao, Jin-Fen
    Asuncion, Bernadette Reyna
    Nakayama, Yuko
    Syn, Nicholas
    Fazreen, Zul
    Soong, Richie
    Kono, Koji
    Yong, Wei-Peng
    GASTRIC CANCER, 2021, 24 (03) : 611 - 623
  • [22] Monoclonal antibodies targeting PD-1, LAG-3, and TIM-3 do not cause reproductive or endocrine toxicity in a syngeneic model of triple negative breast cancer
    De La Cruz, Payton
    Ribeiro, Jennifer
    Grive, Kathryn
    CANCER RESEARCH, 2023, 83 (07)
  • [23] Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome
    Ciraolo, Elisa
    Althoff, Stefanie
    Russ, Josefine
    Rosnev, Stanislav
    Butze, Monique
    Puhl, Miriam
    Frentsch, Marco
    Bullinger, Lars
    Na, Il-Kang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
  • [24] Role of PD-1 and LAG-3 in cancer immunotherapy.
    Drake, Charles G.
    CANCER RESEARCH, 2013, 73
  • [25] LAG-3 and PD-1 blockade raises the bar for melanoma
    Robert, Caroline
    NATURE CANCER, 2021, 2 (12) : 1251 - 1253
  • [26] Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
    Saleh, Reem
    Toor, Salman M.
    Khalaf, Sarah
    Elkord, Eyad
    VACCINES, 2019, 7 (04)
  • [27] LAG-3 and PD-1 blockade raises the bar for melanoma
    Caroline Robert
    Nature Cancer, 2021, 2 : 1251 - 1253
  • [28] Combined Immunotherapy for Melanoma: inhibit PD-1 and LAG-3
    Freyer, Martina
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (10) : 446 - 446
  • [29] PD-1 says goodbye, TIM-3 says hello
    Diana Romero
    Nature Reviews Clinical Oncology, 2016, 13 : 203 - 203
  • [30] Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?
    Abi-Aad, Sasha-Jane
    Zouein, Joseph
    Chartouni, Antoine
    Naim, Nabih
    Kourie, Hampig Raphael
    IMMUNOTHERAPY, 2023, 15 (08) : 611 - 618